ReviewFrontiers in pediatrics2026
Wiskott-Aldrich syndrome and X-linked thrombocytopenia: a review of the clinical and immunological spectrum with a case presentation highlighting glomerulonephritis.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency caused by mutations in the WAS gene, characterized by thrombocytopenia, eczema, recurrent infections, and immune dysregulation. Its milder form, X-linked thrombocytopenia (XLT), exhibits variable autoimmune manifestations. Renal involvement, particularly glomerulonephritis, is uncommon but clinically significant. Case presentation: We report a 10-year-old boy presenting with severe thrombocytopenia, hyporegenerative anemia, nephritic-range proteinuria, and hematuria, alongside multiple autoantibodies including antiglomerular basement membrane, antineutrophil cytoplasmic antibodies, and antinuclear antibodies. His complement levels were reduced and immunoglobulins elevated. Kidney biopsy revealed IgA nephropathy (Oxford M0 E0 S0 T1 C0) with 30% interstitial fibrosis. Bone marrow studies demonstrated near-complete absence of megakaryocytes. The patient's family history was notable for thrombocytopenia in the mother and younger brother. Genetic testing confirmed a homozygous c.599+5G>A WAS variant, consistent with XLT. Literature review: To contextualize these findings, data from the literature, including the IPINet registry (117 patients with WAS/XLT), were reviewed. WAS patients frequently exhibited invasive infections and diverse autoimmune manifestations, including hemolytic anemia, vasculitis, inflammatory bowel disease, arthritis, nephropathy, and celiac disease. Discussion: Dysregulated T- and B-cell function in WAS/XLT promotes autoantibody formation, contributing to renal injury. IgA nephropathy is the predominant glomerular pathology, mediated by circulating immune complexes containing aberrantly glycosylated IgA1. Conclusion: This case illustrates the broad spectrum of autoimmunity in WAS/XLT, highlighting the potential for renal involvement. It emphasizes the importance of early recognition, genetic confirmation, and multidisciplinary management. Registry data remain essential for guiding prognosis, monitoring complications, and informing therapeutic strategies, including hematopoietic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.